News | August 04, 2021
Solara Active Pharma Science clocks net profit of Rs 50.13 crore in Q1FY22
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Aditya Puri former MD of HDFC bank joins Solara board as chairman
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
Aurobindo has one of the most enduring generics ecosystems among peers
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Subscribe To Our Newsletter & Stay Updated
